GLP1 Support

Tools

Four tools for working out where you are. None of them give medical advice, and none of them replace a clinician.

By The GLP1 Support team · Last reviewed September 2026

A syringe, a glass vial and a notepad laid out on a pale surface

Every one of these is for orientation. They do arithmetic and organise questions. They do not know your history, they cannot examine you, and they are not a substitute for the person who can.

Titration schedule viewer

The escalation pattern most prescribers follow. Your own schedule may differ; this is for orientation, not instruction.

Weeks 1–40.25 mgStarting dose. Not a therapeutic dose for weight. It exists to let the gut adjust.
Weeks 5–80.5 mgFirst increase. Nausea, where it appears, usually shows up in the days after a step up.
Weeks 9–121.0 mgSome people hold here indefinitely. There is no requirement to keep climbing.
Weeks 13–161.7 mgOnly where tolerated and the prescriber judges more is warranted.
Week 17 on2.4 mgMaintenance ceiling for the weight-management indication.

Schedules for the other compounds in the library are not yet verified. See the compound library.

Reconstitution calculator

This does arithmetic. It does not check whether the dose you have entered is a dose you should be taking, because it cannot know that.

Concentration
2.50 mg/mL
Draw (U-100 units)
10
Doses per vial
20.0

Errors here happen by factors of ten, usually by confusing syringe units with milligrams. Check the result against your prescriber's instruction before drawing anything, and work it on paper once the first time at any new concentration.

Side-effect lookup

Frequencies shown are from the trials named on each compound page and are averages across trial populations. Yours is a sample of one. Anything on the "call your prescriber" list on our managing page is not something to look up and wait out.

Reported side effects: Semaglutide

44%
Nausea
Placebo 17%
32%
Diarrhoea
Placebo 16%
25%
Vomiting
Placebo 7%
23%
Constipation
Placebo 10%
20%
Abdominal pain
14%
Headache

Rates are from STEP 1, which followed 1,961 adults for 68 weeks on 2.4 mg weekly. The placebo figures matter as much as the drug figures: roughly one in ten people on placebo reported constipation and nearly one in five reported nausea, so not everything you feel on this drug is caused by it. Gastrointestinal effects of some kind were reported by 74% on semaglutide against 48% on placebo. Most were mild to moderate and clustered around dose increases. 7.0% of participants stopped treatment because of adverse events, against 3.1% on placebo. Gallbladder disorders, mostly gallstones, occurred in 2.6% against 1.2% on placebo.

Is a GLP-1 right for me?

Eight questions that produce a printable list to take to your clinician. There is no score and no verdict. Nothing you enter leaves this page or is stored.

What are you hoping this changes?
Have you or a close family member had medullary thyroid carcinoma, or MEN2?
Are you pregnant, breastfeeding, or planning a pregnancy within the next year?
Have you ever had pancreatitis or gallbladder disease?
Do you take insulin or a sulfonylurea?
Do you use oral contraceptives?
Do you have a plan for protein intake and resistance training?
Could you sustain the cost beyond twelve months?

Take this to your clinician

Answer the questions above and your summary appears here.

This summary is a list of things to raise. It is not an assessment, a diagnosis, or an opinion about whether these medications are appropriate for you. Only a clinician who knows your history can tell you that.

Educational only. Nothing here is medical advice, and nothing here substitutes for a conversation with a licensed clinician who knows your history. Dosing, side effects and outcomes vary between people.